Overview

Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized With COVID-19

Status:
Completed
Trial end date:
2021-08-23
Target enrollment:
Participant gender:
Summary
Study to assess the safety and efficacy of STI-5656 (Abivertinib Maleate) plus SOC versus SOC in subjects hospitalized with COVID-19
Phase:
Phase 2
Details
Lead Sponsor:
Sorrento Therapeutics, Inc.
Treatments:
Abivertinib
Maleic acid